Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Main Article Content
Keywords
Ritlecitinib, Adolescent, Integrated Efficacy, Alopecia Areata, ALLEGRO, long-term, JAK3/TEC family kinase inhibitor
Abstract
Introduction: We report updated efficacy results of ritlecitinib up to 3 years in adolescents with alopecia areata (AA) from the ALLEGRO phase 2b/3 and open-label ALLEGRO-LT phase 3 studies.
Methods: Patients aged 12-17 years with AA and ≥50% scalp hair loss who received daily ritlecitinib 50-mg in ALLEGRO-2b/3 and rolled over to ALLEGRO-LT (in which they continued to receive 50 mg) were included. Continuation criteria for adolescents in ALLEGRO-LT required ≥50% improvement in Severity of Alopecia Tool (SALT) score by Month 3 for rollover patients from ALLEGRO-2b/3 and SALT score ≤20 by Month 6 in ALLEGRO-LT for all patients. Patients who received placebo and switched to ritlecitinib were re-baselined to align time points across groups. Data are reported as observed and imputed (last observation carried forward, LOCF) at the data cutoff date (June 25, 2024).
Results: Of 27 adolescents included, 1 was ongoing at the data cutoff, 8 discontinued from ALLEGRO-LT due to availability of commercial drug, 1 completed ALLEGRO-2b/3 and did not rollover to ALLEGRO-LT, and 17 discontinued for other reasons (5 due to not meeting continuation criteria). At 3 years, 84.6% (11/13 observed) and 48.2% (13/27 LOCF) of adolescents had SALT score ≤20; SALT score ≤10 response rates were 76.9% (10/13 observed) and 40.7% (11/27 LOCF). Patients’ Global Impression of Change (PGI-C) response (“moderately” or “greatly” improved) rates were 100.0% (9/9 observed) and 73.1% (19/26 LOCF) at 3 years. Among adolescents with abnormal Eyebrow Assessment (EBA) or Eyelash Assessment (ELA) at baseline, EBA response rates were 100.0% (6/6 observed) and 57.9% (11/19 LOCF), and ELA response rates were 66.7% (4/6 observed) and 64.7% (11/17, LOCF). The decreasing number of adolescents who reached later study time points limits data interpretation.
Conclusion: In adolescents with AA, ritlecitinib 50 mg had long-term clinician- and patient-reported efficacy up to 3 years.
Funding: This study was funded by Pfizer Inc.
References
2. King B, et al. Lancet. 2023; 401:1518-1529
3. Hordinsky M, et al. Pediatr Dermatol. 2023;40: 1003-1009.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.